Richard C. Chao

Suggest Changes
Learn More
PURPOSE Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in(More)
4008 Background: In a double-blind phase 3 trial, SU improved PFS vs PBO (11.4 vs 5.5 months; HR 0.418, 95% CI 0.263, 0.662; p=0.0001) and was well tolerated in pts with advanced well-differentiated,(More)